Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Psoriasis REPLY

被引：0
|
作者：
Papp, Kim A. [1 ]
机构：
[1] Prob Med Res, Waterloo, ON, Canada
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2012年 / 367卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：275 / 275
页数：1
相关论文
共 50 条
  • [31] Response to brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal
    Leonardi, C.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (04) : 714 - 715
  • [32] Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial
    Okubo, Yukari
    Kobayashi, Satomi
    Murakami, Masamoto
    Sano, Shigetoshi
    Kikuta, Natsuko
    Ouchi, Yoshiumi
    Terui, Tadashi
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2024, 25 (05) : 837 - 847
  • [33] A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
    Genovese, Mark C.
    Greenwald, Maria
    Cho, Chul-Soo
    Berman, Alberto
    Jin, Ling
    Cameron, Gregory S.
    Benichou, Olivier
    Xie, Li
    Braun, Daniel
    Berclaz, Pierre-Yves
    Banerjee, Subhashis
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 (07) : 1693 - 1704
  • [34] Ixekizumab for psoriasis Reply
    Griffiths, Christopher E. M.
    Papp, Kim A.
    Ball, Susan G.
    Nickoloff, Brian J.
    LANCET, 2016, 387 (10015): : 226 - 227
  • [35] Effect of anti-interleukin-17 biologics on Krebs von den Lungen-6 level in patients with psoriasis
    Hara, Hiromichi
    Miyagawa, Hanae
    Araya, Jun
    Minagawa, Shunsuke
    Numata, Takanori
    Umezawa, Yoshinori
    Asahina, Akihiko
    Nakagawa, Hidemi
    Kuwano, Kazuyoshi
    JOURNAL OF DERMATOLOGY, 2021, 48 (06): : 886 - 893
  • [36] Interleukin 12/23 monoclonal antibody and psoriasis
    Heller, Marissa
    JOURNAL OF DRUGS IN DERMATOLOGY, 2008, 7 (06) : 603 - 603
  • [37] Comparison of Efficacy of Anti-interleukin-17 in the Treatment of Psoriasis Between Caucasians and Asians: A Systematic Review and Meta-Analysis
    Zhang, Danyi
    Qiu, Jianing
    Liao, Xing
    Xiao, Yi
    Shen, Minxue
    Deng, Yaxiong
    Jing, Danrong
    FRONTIERS IN MEDICINE, 2022, 8
  • [38] The effect of treatment with anti-interleukin-17 in patients with allergic contact dermatitis
    Todberg, Tanja
    Zachariae, Claus
    Krustrup, Dorrit
    Skov, Lone
    CONTACT DERMATITIS, 2018, 78 (06) : 431 - 432
  • [39] Anti-interleukin-17 therapies for moderate/severe psoriasis in clinical practice: effectiveness, safety and association with clinical patient factors
    Garcia-Martin, Estela
    Romero-Jimenez, R. M.
    Baniandres-Rodriguez, Ofelia
    Escudero-Vilaplana, Vicente
    Benedi-Gonzalez, Juana
    Luna, Paloma Morales de los Rios
    Herranz-Alonso, Ana
    Sanjurjo-Saez, Maria
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2024, 31 (05) : 409 - 415
  • [40] Comment on "Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial"
    Wang, Lu-Ying
    Ding, Yi-Hang
    Hou, Xiu-Juan
    Li, Chen
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2024, 25 (06) : 1023 - 1024
12345